Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07043634 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects
A Phase 3 study of Bioavailability Heathy Volunteers, sponsored by Sarfez Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07043634 is a Phase 3 study of Bioavailability Heathy Volunteers that has completed, run by Sarfez Pharmaceuticals. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07043634, a Phase 3 study of Bioavailability Heathy Volunteers, has completed, sponsored by Sarfez Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.
Conditions Studied
Interventions
- COMBINATION_PRODUCT FDC (24 mg ER torsemide and 30 mg Spironolactone) without food
- COMBINATION_PRODUCT FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
Study Locations (1)
Virginia
- Sarfez Pharmaceuticals - Vienna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-06-15 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07043634
The ClinicalTrials.gov registry entry for NCT07043634 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarfez Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bioavailability Heathy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which FDC (24 mg ER torsemide and 30 mg Spironolactone) without food is the first listed.
NCT07043634 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT07043634 about?
NCT07043634 is a clinical study titled "A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects". This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.
What is the current status of trial NCT07043634?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2025-06-15. Estimated completion is 2025-12-30.
What conditions does trial NCT07043634 study?
This clinical trial studies the following conditions: Bioavailability Heathy Volunteers.
What interventions are being tested in trial NCT07043634?
The interventions under investigation include: FDC (24 mg ER torsemide and 30 mg Spironolactone) without food (COMBINATION_PRODUCT), FDC (24 mg ER torsemide and 30 mg Spironolactone) with food (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07043634?
This trial is sponsored by Sarfez Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07043634 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.